AI Article Synopsis
- A study analyzed primary neuroblastomas from 36 patients to check for the presence of GD2 ganglioside, finding that all tumors expressed this specific glycosphingolipid.
- The mean concentration of GD2 was significant, accounting for 12% of total gangliosides, and remained consistent across different clinical stages.
- In contrast, related, more differentiated tumors showed minimal to no presence of GD2, indicating that GD2 could serve as a sensitive marker and a potential target for immunotherapy in neuroblastoma.
Article Abstract
Primary neuroblastomas obtained before therapy from 36 patients were studied to determine the frequency of tumors expressing a specific glycosphingolipid, GD2 ganglioside. Total tissue gangliosides were purified by a new partition method, quantitated, and analyzed by high-performance thin-layer chromatography. All 36 neuroblastoma tumors, representing all clinical stages, contained GD2 ganglioside. The mean relative and absolute concentrations of GD2 were substantial (12% of the total tissue gangliosides and 50 nmol/g of tissue) and were independent of the clinical stage of the tumor. In contrast, 6 samples of related but more differentiated tumors (ganglioneuroblastoma and ganglioneuroma) had little or no detectable GD2 (less than or equal to 1.5% of total gangliosides and less than or equal to 4 nmol/g of tissue). These results suggest that GD2 is a sensitive marker for neuroblastoma tissue and may be an excellent target antigen for immunotherapy of this tumor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma.
Liver Int
January 2025
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Background & Aims: GD2, a member of the ganglioside (GS) family (sialic acid-containing glycosphingolipids), is a potential biomarker of cancer stem cells (CSC) in several tumours. However, the possible role of GD2 and its biosynthetic enzyme, GD3 synthase (GD3S), in intrahepatic cholangiocarcinoma (iCCA) has not been explored.
Methods: The stem-like subset of two iCCA cell lines was enriched by sphere culture (SPH) and compared to monolayer parental cells (MON).
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
J Hematol Oncol
December 2024
Department of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, San Paolo N°15 Street, 00146, Rome, Italy.
Sarcomas are rare, mesenchymal tumors, representing about 10-15% of all childhood cancers. GD2 is a suitable target for chimeric antigen receptor (CAR) T-cell therapy due to its overexpression in several solid tumors. In this preclinical study, we investigated the potential use of iCasp9.
View Article and Find Full Text PDFAction Mechanisms of Exosomes Derived from GD3/GD2-Positive Glioma Cells in the Regulation of Phenotypes and Intracellular Signaling: Roles of Integrins.
Int J Mol Sci
November 2024
Department of Biomedical Sciences, Chubu University, Matsumoto 1200, Kasugai 487-8501, Aichi, Japan.
Extracellular vesicles (EVs) play important roles in intercellular communication in various biological events. In particular, EVs released from cancer cells have attracted special attention. Although it has been reported that cancer-associated glycosphingolipids play important roles in the enhancement of malignant properties of cancer cells, the presence, behavior, and roles of glycosphingolipids in EVs have not been elucidated.
View Article and Find Full Text PDFCopper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.
Nat Commun
December 2024
School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma.
View Article and Find Full Text PDFProspects of anti-GD2 immunotherapy for retinoblastoma.
Front Immunol
December 2024
Affiliated Hospital of Shandong Second Medical University,School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Article Synopsis
- - Retinoblastoma is the most common eye tumor in young children, and existing treatments like chemotherapy and surgery can have serious side effects, including blindness and toxic reactions.
- - Immunotherapy, especially targeting the GD2 sphingolipid found on retinoblastoma cells, shows promise due to its lower toxicity and potential to improve patient quality of life.
- - Anti-GD2 therapies, such as the monoclonal antibody Dinutuximab, CAR-T therapy, GD2 vaccines, and nanoparticles are emerging as effective treatments, but there are still challenges to overcome in their application.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!